Get the Stockscreener App
1.85
1.07%
-0.02
After Hours:
1.85
Aldeyra Therapeutics Inc stock is traded at $1.85, with a volume of 4.53M.
It is down -1.07% in the last 24 hours and down -66.30% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.87
Open:
$1.98
24h Volume:
4.53M
Relative Volume:
1.77
Market Cap:
$111.34M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-3.2813
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
+30.28%
1M Performance:
-66.30%
6M Performance:
-62.63%
1Y Performance:
-72.31%
1-Day Range:
$1.76
$2.02
1-Week Range:
$1.37
$2.33
52-Week Range:
$1.07
$6.73
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.85 | 112.54M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra ... - Bluefield Daily Telegraph
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
Does Aldeyra Therapeutics (ALDX) have the potential to rally 79.28% as Wall Street analysts expect? - MSN
BTIG Reiterates Aldeyra Therapeutics (ALDX) Buy Recommendation - MSN
Rosen Law Firm Investigating Potential Securities Claims Against Aldeyra Therapeutics - National Today
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), ... - Bluefield Daily Telegraph
ALDX Investor News: If You Have Suffered Losses in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action InvestigationALDX - Barchart.com
Insider Buying: Richard Douglas Acquires 70,000 Shares of Aldeyra Therapeutics Inc (ALDX) - GuruFocus
Aldeyra therapeutics director Douglas buys $98,000 in ALDX By Investing.com - Investing.com India
Insider Makes Bold Move on Aldeyra Therapeutics Stock - TipRanks
Insider Buying: Richard Douglas Acquires 70,000 Shares of Aldeyr - GuruFocus
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX - The Joplin Globe
ALDX PE Ratio & Valuation, Is ALDX Overvalued - Intellectia AI
Aldeyra therapeutics director Douglas buys $98,000 in ALDX - Investing.com
Director buys 70K Aldeyra Therapeutics (ALDX) shares at $1.40 - Stock Titan
Why Did ALDX Stock Tank 70% Today? - Stocktwits
ALDX crashes 71% as FDA issues third CRL for dry eye disease drug NDA - MSN
FDA rejects Aldeyra's dry eye drug for third time, stock crashes 68% - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - PR Newswire
Aldeyra Therapeutics CFO Alfieri buys $7,100 in stock By Investing.com - Investing.com Australia
Insider Buying: Michael Alfieri Acquires Additional Shares of Al - GuruFocus
Aldeyra Therapeutics CFO Alfieri buys $7,100 in stock - Investing.com
Aldeyra Therapeutics (ALDX) finance chief buys 5,000 shares - Stock Titan
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects - marketscreener.com
What's Going On With Aldeyra Therapeutics Stock On Thursday? - Benzinga
BTIG Maintains Buy on Aldeyra Therapeutics, Inc. (ALDX) March 2026 - Meyka
HC Wainwright & Co. downgrades Aldeyra Therapeutics (ALDX) - MSN
Aldeyra’s CEO to Lead Strategic Discussions at Healthcare Conference - StocksToTrade
Shareholder Alert: Ademi LLP Investigates Claims of Securities F - GuruFocus
Potential Securities Fraud: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) - The Globe and Mail
Aldeyra Eyes Growth as CEO Prepares for Key Conference - timothysykes.com
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Aldeyra Therapeutics, Inc. - Barchart.com
Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection - BioPharma Dive
ALDX Plummets 71% Following FDA's Third Complete Response Letter for Dry Eye Disease Drug Application - Bitget
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA - The Globe and Mail
Upcoming Conference Sheds Light on Aldeyra Therapeutics’ Innovations - StocksToTrade
Aldeyra shares plunge after third FDA rejection for reproxalap - The Pharma Letter
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
ALDX Stock Downgraded by HC Wainwright & Co. with Price Target R - GuruFocus
H.C. Wainwright cuts Aldeyra stock rating on FDA setback - Investing.com
HC Wainwright Downgrades Aldeyra Therapeutics to Neutral From Buy, Adjusts PT to $2 From $10 - marketscreener.com
FDA issues CRL to Aldeyra’s reproxalap drug application - Yahoo Finance
Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy DataHas The Bull Case Changed? - simplywall.st
FDA rejects Aldeyra’s dry eye disease drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalap - geneonline.com
Aldeyra Therapeutics (ALDX) Faces Major Setback as FDA Rejects E - GuruFocus
Aldeyra Therapeutics stock maintained at Buy by BTIG after FDA setback - Investing.com South Africa
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):